Navigation Links
U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
Date:9/5/2012

RARITAN, N.J., Sept. 5, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.

The FDA grants priority review to medicines that may offer major advances in care or provide a treatment option where no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA will aim to complete its review within six months of the NDA submission. The NDA was submitted June 29.

"There is a growing public health need for new treatment options for multi-drug resistant tuberculosis. If approved, bedaquiline would offer the first in a new class of anti-tuberculosis drugs for patients suffering from this serious and deadly disease," said Wim Parys, M.D., Head of the Infectious Diseases therapeutic area at Janssen. "We are working closely with the FDA and other regulatory agencies in high-burden countries to quickly bring bedaquiline to the patients who need it."  

The regulatory submission was supported by 24-week data from the Phase II clinical development program, which includes an open-label study and a controlled, randomized trial that evaluated the safety and efficacy of bedaquiline versus placebo in the treatment of patients with pulmonary MDR-TB in combination with a background regimen.

Bedaquiline is a diarylquinoline discovered by scientists at Janssen.

About Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
10. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
11. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... /PRNewswire-iReach/ -- The 2013 Pharma ChemOutsourcing Show slated for ... number of "Emerging" small molecule biotech company chemists ... .  "No one saw this coming", commented ... still 4 months away and we may end up ... surprise and great news for attendees". Thecurrent list of ...
(Date:5/21/2013)... , May 21, 2013  Cephasonics, ... platform, today announced the introduction of the ... complete network-based communications with all cQuest Ultrasound™ ... embedded-ultrasound technology, including this new capability, at ... Paulo, Brazil from May 21-24.  ...
(Date:5/21/2013)... , May 21, 2013 BioElectronics ... drug-free consumer electronic devices, announced that CEO, ... today to the FDA,s Medical Advisory Committee, Orthopedic ... company,s products for over the counter sales. ... developed its medical device classification schema," Whelan said.  ...
Breaking Medicine Technology:Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... and NEEDHAM, Mass., March 19, 2012  Oridion (SIX ... Index™, one of the Smart Capnography™ family of ... survey conducted at the October 2011 ... (ASA) conference in Chicago. Respondents showed a clear preference ...
... International, Inc. (SGLN.PK) and SurgLine, Inc. ("SurgLine") today announced ... SurgLine have completed the return of over 1,000,000,000 shares of ... up to the previous press release whereby the executives of ... of the restricted shares they were issued of SGLN in ...
Cached Medicine Technology:Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 2Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 3Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 4SurgLine International, Inc. Announces Over 1 Billion Shares Returned to Company 2
(Date:5/21/2013)... from SOURCE XT one of the largest, post-approval ... today at EuroPCR 2013 show good clinical outcomes in ... for all access approaches, valve sizes and delivery systems. ... consecutively enrolled patients (mean age 81.5 years) undergoing TAVI ... in 17 countries between July 2010 and October 2011. ...
(Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
(Date:5/21/2013)... According to a May 13, 2013 New ... Botox,” Botox injections have become the most popular ... (Go to goo.gl/8iYbD). Although it is mostly associated with women, ... injection makes facial wrinkles less visible by paralyzing facial muscles. ... three months. This means that people who are conscious about ...
(Date:5/21/2013)... 21, 2013 The federal judge overseeing ... lawsuits in U.S. District Court, Northern District ... a request from Plaintiffs’ Counsel to conduct Ex Parte ... May 17th Order grants that request, and sets forth ... re: Wright Medical Technology, Inc., Conserve Hip Implant Products ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... completes successful first year , ... Monrovia, Liberia (Vocus) ... increased access to health care for Liberia,s citizens is the availability ... of rebuilding, much of the country,s infrastructure is still in ruins, ...
... of the most debilitating diseases known to man, and new findings ... News Report website. To read the entire report about the ... , ... Boca Raton, Fla. (PRWEB) November 14, 2008 ...
... school, dips in academic performance and classroom participation can ... students to accept newcomers can go a long way ... the conclusion of a new longitudinal study that found ... to declines in academic performance and classroom participation, but ...
... VIRGINIA BEACH, Va., Nov. 13, 2008 James G.,Carlson, Chairman ... statement on America,s "Premature Birth Report Card," which was,released November ... in America deserves a fair chance to grow up in ... clear with its ,Premature,Birth Report Card, that is not the ...
... Marks for its Lack of Overall Plan and,Sense of ... (LCA-CA) issued its 1st annual Report Card on Lung ... to the state for its lack,of progress in reducing ... year than all other major cancer combined., (Logo: ...
... fourth annual EagleBank,Foundation Fight Breast Cancer Golf Classic ... primary beneficiaries: Shady Grove,Adventist Hospital and Suburban Hospital ... Hospital, Providence Hospital and Washington,Hospital Center in Washington, ... Montgomery County. The tournament was held on October ...
Cached Medicine News:Health News:Mercy Ships Ensures That Liberian Technicians "know how to fix it" 2Health News:Mercy Ships Ensures That Liberian Technicians "know how to fix it" 3Health News:Mercy Ships Ensures That Liberian Technicians "know how to fix it" 4Health News:Alzheimer's Disease Cutting Edge Research Announced on Natural Health News Report Website 2Health News:Supportive teachers, peers can ease negative effects of frequent moves in elementary school 2Health News:AMERIGROUP Chairman and CEO Urges Action to Improve Nation's 'Premature Birth Report Card' 2Health News:Lung Cancer Alliance-California Issues Inaugural State-Specific Report Card on Lung Cancer 2Health News:Fourth Annual EagleBank Foundation Fight Breast Cancer Golf Classic Raises Over $100,000 2
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 30 nm 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: